Please use this identifier to cite or link to this item:
Title: Advancing the repurposing of ivermectin for malaria
Author: Chaccour, Carlos
Rabinovich, Regina
Keywords: Malària
Malalties parasitàries
Parasitic diseases
Issue Date: 13-Mar-2019
Publisher: Elsevier
Abstract: There is ever-increasing anticipation for the potential of mass drug administration of endectocides (also known as systemic insecticides) to reduce malaria transmission, with ivermectin emerging as the most likely first-in-class endectocide. More than half of the 46 papers published on this subject in the past decade appeared in the past 2 years. 23 projects are registered in the MESA Track database, of which seven are active today; and, more importantly, trial mapping by the Malaria Ivermectin Roadmap shows that abundant new evidence on the topic will be available by 2020. Why is there so much interest in repurposing ivermectin? After achieving remarkable advances from 2000 to 2015, the global fight against malaria has stalled. Beyond funding and access gaps, residual transmission—driven by mosquito behavioural adaptations that allow avoidance of home-based insecticides—has become a key liability for vector control, and challenges achievement of the global goals set forth by WHO.
Note: Reproducció del document publicat a:
It is part of: The Lancet, 2019, vol. 393, num. 10180, p. 1480-1481
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
PIIS0140673618326138.pdf104.02 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons